Stocktoria
Denali Therapeutics Inc. DNLI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2017-12-08
Chart by TradingView
3/9
Piotroski F — financial health
3.62
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $0 | $330.5M | $108.5M | $48.7M |
| Operating income | -$555.3M | -$487.3M | -$196.7M | -$340.7M | -$295.8M |
| Net income | -$512.5M | -$422.8M | -$145.2M | -$326.0M | -$290.6M |
| Operating cash flow | -$412.6M | -$347.7M | -$358.0M | -$244.7M | -$211.4M |
| Free cash flow | -$422.1M | -$363.6M | -$370.9M | -$262.5M | -$219.9M |
| Total assets | $1.1B | $1.4B | $1.2B | $1.5B | $1.4B |
| Total liabilities | $131.1M | $144.5M | $123.0M | $417.8M | $441.9M |
| Shareholders' equity | $1.0B | $1.2B | $1.0B | $1.0B | $962.3M |
| Ratios | |||||
| Operating margin | — | — | -59.5% | -314.2% | -607.8% |
| Net margin | — | — | -43.9% | -300.6% | -597.2% |
| FCF margin | — | — | -112.2% | -242.1% | -451.9% |
| Return on assets | -44.8% | -30.8% | -12.6% | -22.3% | -20.7% |
| Return on equity | -50.6% | -34.4% | -14.1% | -31.3% | -30.2% |
| Current ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 |
| Revenue growth | — | -100.0% | 204.7% | 122.9% | -85.5% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 45,200 | $867,840 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.62 (safe)
- Working capital / assets 0.701
- Retained earnings / assets -1.792
- EBIT / assets -0.485
- Equity / liabilities 7.733
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001714899 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.